Ohad Benjamini

2.0k total citations
56 papers, 920 citations indexed

About

Ohad Benjamini is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Ohad Benjamini has authored 56 papers receiving a total of 920 indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Genetics, 27 papers in Pathology and Forensic Medicine and 19 papers in Hematology. Recurrent topics in Ohad Benjamini's work include Chronic Lymphocytic Leukemia Research (38 papers), Lymphoma Diagnosis and Treatment (26 papers) and Chronic Myeloid Leukemia Treatments (15 papers). Ohad Benjamini is often cited by papers focused on Chronic Lymphocytic Leukemia Research (38 papers), Lymphoma Diagnosis and Treatment (26 papers) and Chronic Myeloid Leukemia Treatments (15 papers). Ohad Benjamini collaborates with scholars based in Israel, United States and United Kingdom. Ohad Benjamini's co-authors include Osnat Bairey, Abraham Avigdor, Michael J. Keating, Preetesh Jain, Arnon Nagler, William G. Wierda, Hagop M. Kantarjian, Tamar Tadmor, Galia Rahav and Susan O’Brien and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Ohad Benjamini

50 papers receiving 906 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ohad Benjamini Israel	15	392	281	274	247	199	56	920
Beenu Thakral United States	18	406 1.0×	411 1.5×	348 1.3×	499 2.0×	204 1.0×	114	1.2k
Dolors Costa Spain	21	417 1.1×	280 1.0×	190 0.7×	400 1.6×	126 0.6×	73	1.2k
Ronit Gurion Israel	17	216 0.6×	344 1.2×	381 1.4×	237 1.0×	102 0.5×	83	830
Viviane Dubruille France	20	605 1.5×	241 0.9×	405 1.5×	872 3.5×	127 0.6×	68	1.4k
Jeanette Carreras United States	15	303 0.8×	279 1.0×	345 1.3×	485 2.0×	204 1.0×	39	988
Andrea Assanelli Italy	18	249 0.6×	373 1.3×	263 1.0×	416 1.7×	455 2.3×	47	1.2k
Kazutaka Sunami Japan	18	222 0.6×	293 1.0×	530 1.9×	667 2.7×	182 0.9×	115	1.2k
Goretta Bonacorsi Italy	16	204 0.5×	215 0.8×	276 1.0×	110 0.4×	137 0.7×	34	710
James Weisberger United States	15	235 0.6×	363 1.3×	266 1.0×	118 0.5×	104 0.5×	28	662
Stanley M. Marks United States	14	356 0.9×	299 1.1×	264 1.0×	240 1.0×	166 0.8×	32	777

Countries citing papers authored by Ohad Benjamini

Since Specialization

Citations

This map shows the geographic impact of Ohad Benjamini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ohad Benjamini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ohad Benjamini more than expected).

Fields of papers citing papers by Ohad Benjamini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ohad Benjamini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ohad Benjamini. The network helps show where Ohad Benjamini may publish in the future.

Co-authorship network of co-authors of Ohad Benjamini

This figure shows the co-authorship network connecting the top 25 collaborators of Ohad Benjamini. A scholar is included among the top collaborators of Ohad Benjamini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ohad Benjamini. Ohad Benjamini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tadmor, Tamar, Toby A. Eyre, Ohad Benjamini, et al.. (2024). BELLWAVE-011: Phase 3 randomized trial of nemtabrutinib versus ibrutinib or acalabrutinib in untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.. Journal of Clinical Oncology. 42(16_suppl). TPS7088–TPS7088. 3 indexed citations

Kedmi, Meirav, Ohad Benjamini, Ginette Schiby, et al.. (2024). Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B‐Cell Lymphoma. Hematological Oncology. 42(6). e70001–e70001.

Tadmor, Tamar, Toby A. Eyre, Ohad Benjamini, et al.. (2024). Phase 3 BELLWAVE-011 Study: Nemtabrutinib Versus Ibrutinib or Acalabrutinib in Previously Untreated Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL). Clinical Lymphoma Myeloma & Leukemia. 24. S182–S182. 1 indexed citations

Tadmor, Tamar, Toby A. Eyre, Ohad Benjamini, et al.. (2024). Nemtabrutinib Versus Ibrutinib or Acalabrutinib for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: The Phase 3, Open-Label, Randomized Bellwave-011 Study. Blood. 144(Supplement 1). 1875.2–1875.2. 2 indexed citations

Niemann, Carsten Utoft, Talha Munir, Carolyn Owen, et al.. (2024). First-Line Ibrutinib Plus Venetoclax Vs Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): Glow Study 64-Month Follow-up (FU) and Adverse Event (AE)-Free Progression-Free Survival (PFS) Analysis. Blood. 144(Supplement 1). 1871–1871. 5 indexed citations

Zinzani, Pier Luigi, Jiřı́ Mayer, Ohad Benjamini, et al.. (2023). A phase 2 study of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B‐cell malignancies: waveLINE‐006. Hematological Oncology. 41(S2). 564–565. 2 indexed citations

Tadmor, Tamar, Ohad Benjamini, Neta Goldschmidt, et al.. (2023). A Prospective, Phase-II Study to Evaluate the Efficacy and Safety of Obinutuzumab, Ibrutinib, and Venetoclax (GIVeRS) in Patients with Richter's Syndrome. Blood. 142(Supplement 1). 4640–4640. 2 indexed citations

Lee, Ainsley Ryan Yan Bin, Lauren Shapiro, Astha Thakkar, et al.. (2022). Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis. European Journal of Cancer. 172. 65–75. 26 indexed citations

Itchaki, Gilad, Ohad Benjamini, Anatoly Nemets, et al.. (2022). "Real-Life" Data of Zanubrutinib in Patients with Waldenström Macroglobulinemia - a Multi-Center Retrospective Study. Blood. 140(Supplement 1). 11981–11982.

10.

Kedmi, Meirav, et al.. (2021). Outcomes Related to FDG-PET-CT Response in Patients With Hodgkin Lymphoma Treated With Brentuximab-Vedotin at Relapse or Consolidation. Clinical Lymphoma Myeloma & Leukemia. 21(12). e929–e937. 6 indexed citations

11.

Davidson, Tima, Ginette Schiby, Stephen Raskin, et al.. (2018). Low rate of spleen involvement in sporadic Burkitt lymphoma at staging on PET-CT. Abdominal Radiology. 43(9). 2369–2374. 9 indexed citations

12.

Jain, Preetesh, et al.. (2018). Long-term control of refractory follicular lymphoma after treatment of secondary acute promyelocytic leukemia with arsenic trioxide (As ₂ O ₃ ) and all-trans retinoic acid (ATRA). Blood Research. 53(2). 169–169. 2 indexed citations

13.

Abraham, Michal, Shiri Klein, Baruch Bulvik, et al.. (2017). The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression. Leukemia. 31(11). 2336–2346. 86 indexed citations

14.

Benjamini, Ohad, Elena Ribakovsky, Meirav Kedmi, et al.. (2016). Evaluation of the Risk of Hepatitis B Reactivation Among Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors. Blood. 128(22). 5429–5429. 6 indexed citations

15.

Benjamini, Ohad, Preetesh Jain, Long Trinh, et al.. (2014). Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leukemia & lymphoma. 56(6). 1643–1650. 102 indexed citations

16.

Jain, Preetesh, Hagop M. Kantarjian, Keyur P. Patel, et al.. (2013). MutatedNPM1in patients with acute myeloid leukemia in remission and relapse. Leukemia & lymphoma. 55(6). 1337–1344. 30 indexed citations

17.

Benjamini, Ohad, Hagop M. Kantarjian, Mary Beth Rios, et al.. (2013). Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience. Leukemia & lymphoma. 55(12). 2879–2886. 32 indexed citations

18.

Benjamini, Ohad, Preetesh Jain, Sergej Konoplev, et al.. (2013). CD4−/CD8− Variant of T-Cell Large Granular Lymphocytic Leukemia or Hepatosplenic T-Cell Lymphoma: A Clinicopathologic Dilemma. Clinical Lymphoma Myeloma & Leukemia. 13(5). 610–613. 8 indexed citations

19.

Benjamini, Ohad, et al.. (2013). Chronic Lymphocytic Leukemia With Central Nervous System Involvement: A High-Risk Disease?. Clinical Lymphoma Myeloma & Leukemia. 13(3). 338–341. 13 indexed citations

20.

Bairey, Osnat, Ohad Benjamini, Dorit Blickstein, Avishay Elis, & Rosa Ruchlemer. (2006). Non-Hodgkin's lymphoma in patients 80 years of age or older. Annals of Oncology. 17(6). 928–934. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact